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Objectives: Few studies have attempted to quantify the costs of operating room 
(OR) time. The purpose of this study is to quantify the variable cost per OR min-
ute in isolated non-robotic valvular procedures – aortic valve replacement (AVR), 
mitral valve replacement (MVR), and mitral valve repair (MVRepair). MethOds: 
The Premier database, one of the most comprehensive hospital databases, was 
queried from 2007 to 2011 for patients undergoing AVR, MVR, or MVRepair. This 
database contains complete billing, hospital cost, and coding data from > 600 US 
facilities. Patients were identified using the following International Classification 
of Diseases 9th Revision (ICD-9) procedure codes: AVR 35.21, 35.22; MVR 35.23, 
35.24; and MVRepair 35.12. Patients having coronary artery bypass grafting were 
excluded. The surgical approaches, right thoracotomy (RT) and any sternal inci-
sion, were identified for each patient with expert clinical assistance. Patients 
with right thoracotomy were then propensity score matched to patients with 
any sternal incision, adjusting for patient differences. Premier classified vari-
able costs of the OR into three categories; staff for the surgery room, anesthe-
sia, and recovery room. Outliers were identified based on the cost per minute 
of the procedure. The top and bottom five percent were removed. All costs were 
adjusted to 2012 dollars using the Medical Care Component of the Consumer Price 
Index. Results: There were 2,657 valvular procedures - 1,604 AVR, 434 MVR, and 
619 MVRepair - that met the inclusion criteria. The average cost per OR minute 
was $28.5 (95% CI $28.1 - $28.9) for all procedures, and $27.8 (95% CI $27.3 – $28.3), 
$31.7 (95% CI $29.5 - $31.9), $28.7 (95% CI $27.9 - $29.5) for AVR, MVR, and MVRepair, 
respectively. cOnclusiOns: Quantifying the variable cost of an OR minute from 
a multi-institution database provides researchers with an important component 
to use in economic evaluations for valvular procedures.
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Objectives: The purpose of this study was to find the trends in total medical 
expenditure and utilization patterns of medical resource for heart failure inpatients 
between years of 2009 and 2011. MethOds: Heart failure patient was defined as 
the one with I50, which is the primary diagnosis ICD-10 code. Patients were iden-
tified from the Korea National Health Insurance Claim’s Sample data in Health 
Insurance Review & Assessment Service (HIRA_NIS data) of 2009 (Serial Number: 
HIRA_NPS_2009-0071) and 2011 (Serial Number: HIRA_NIS_2011-0067). The HIRA_NIS 
data contain 13% of overall inpatient and 1% of ambulatory patient data including 
medical costs and resource utilizations of the patients in Korea (about 1.1 million 
persons per year). The estimated number of total researched patients were 7,410 in 
2009, comprised of 2,571 inpatients and 6,010 outpatients. In 2011, the estimated 
number of patients were 8,557; 2,803 inpatients and 7,189 outpatients. Results: 
The average medical expenditure per inpatient with heart failure had increased to 
14.9% between two years. For all types of hospitals studied, university hospital, gen-
eral hospital, and secondary hospital, the medical cost per inpatient had increased. 
The length of hospitalization had increased to 8.4% in 2011 compared with 2009. In 
both years, essential hypertension and arterial fibrillation & flutter were the most 
prevalent secondary diseases for heart failure inpatients, followed by non-insulin-
dependent diabetes mellitus in 2009 and angina pectoris in 2011. cOnclusiOns: 
Heart failure was a serious disease in terms of the medical expenditure for treat-
ment and the length of hospitalization in both years. The medical expenditure was 
increasing with time. Considering this trend, it can be expected that the economic 
burden for patients, hospitals, and the health care system will continuously be 
increased.
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Objectives: High cholesterol is one of the major risk factors for coronary heart 
disease. The objectives of this study were to examine the prevalence of antihy-
perlipidemic agents use, and provide estimates of the associated outpatient pre-
scription drug utilization and expenditure. MethOds: A cross-sectional study was 
conducted using data from the Medical Expenditure Panel Survey (MEPS) between 
2002 and 2010. Subjects were derived from U.S. civilian and non-institutionalized 
population diagnosed with hyperlipidemia. A series of descriptive analyses were 
performed to estimate the weighted prevalence, utilization, and expenditures for 
the hyperlipidemic patients who received any FDA-approved lipid lowering agent. 
SAS 9.3 statistical software was used for all analyses including sample weights and 
standard error adjustments. Results: The study findings indicated the patients 
diagnosed with hyperlipidemia increased from 17 million to 41 million between 
2002 and 2010. Among these, 94.1% in 2002 vs. 87.8% in 2010 of the patients received 
antilipidemic drugs. However, the utilization of total lipid lowering agents increased 
from 96 million in 2002; to 149 million in 2005; then to 231 million in 2010. The 
drug expenditures showed a significant increase by $12 billion rising from $11.7 
billion in 2002 to $22.8 billion in 2010. cOnclusiOns: Despite the prevalence of a 
noted increase of treatment, utilization and expenditures for those diagnosed with 
hyperlipidemia, there exists a large population of people who remain untreated. 
The study results indicate that further research is needed to improve treatment of 
hyperlipidemia as well as assessing the impact on costs and health care outcomes 
from untreated patients over time.
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Objectives: The purpose of this study was to find the total medical expenditure 
and utilization of trends in medical resource for patients hospitalized and diag-
nosed with heart failure. MethOds: : Heart failure patients were identified from 
the Korean HIRA_NIS Data (National Health Insurance Claims’ Sample data) of 
2011, provided by Health Insurance Review & Assessment Service (HIRA) in South 
Korea. Heart failure inpatient was defined as the one whose primary diagnosis 
ICD-10 code is I50. The analysis of relations between total medical expenditure 
and possible variables are processed through regression analysis. Results: The 
average medical cost per inpatient with heart failure was KRW 3,167,969 (USD 
2,970.16). The medical cost per inpatient showed KRW 3,627,711 (USD 3,401.19) 
KRW 2,500,556 (USD 2,344.42) KRW 1,668,074 (USD 1,563.92) in the university hos-
pitals, general hospitals, and secondary hospitals, respectively. The number of visit 
to hospital for each patient was 1.7 times per year. The average hospital stay for 
inpatient was 24.6 days. The essential hypertension, arterial fibrillation and flutter, 
and angina pectoris were ranked to be the most prevalent secondary disease for 
heart failure in-patients. According to the result of multivariate regression analy-
sis, with observation of 8,557 heart failure inpatients, factors including the age of 
40 and over, male, visit days and renal impairment showed a significant increase 
in total medical expenditure. Especially, renal impairment was the largest impact 
on the increase in treatment cost of heart failure (coefficient= 2,831,614 SD 123,951, 
p< 0.001). cOnclusiOns: Although extra billing cost could not be identified with 
NHI claims data, this analysis suggests that heart failure is a considerable disease 
with great medical expenditure. In consideration of total medical expenditure, it 
can be expected that patients, hospitals, and national health care department are 
currently in severe economic burden.
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Objectives: Advanced heart failure (HF) is a leading cause of death in developed 
countries. One to two percent of the French population is affected by this disease. 
It also causes a substantial economic burden on society and cost 1.6 billion euros 
per year in France. Usually, cardiac transplantation is the most effective treatment. 
However, because of a limited donor organ supply, innovative technics as left ven-
tricular assist devices (LVAD) were developed for over 10 years. This study aims to 
assess the medical and economic consequences of LVAD in adults with advanced HF 
in France during one year after LVAD implantation. MethOds: The primary medi-
cal outcome was the discharge to the patient’s home. Secondary medical outcomes 
were defined as final situation of patient, survival, dependence and quality of life 
(QOL) assessed with the SF-36 and the Minnesota QOL questionnaires. This prospec-
tive economic analysis adopted the health care payer’s perspective and took into 
account direct medical and non-medical costs. Results: Among the 55 patients 
included, 37 were discharged at home during an average of 140 days. At one year, 
23 patients were still on device and spent 238 days at home, 15 were transplanted 
and spent 132 days at home and 17 were died and spent 13 days at home. The mean 
total cost per implanted patient was 164,154±37,104€ . Costs drivers were the device 
(58%) and initial hospitalization (30%). The cost of at home care was 6,084±6,738€ 
accounting for only 4% of total cost. According to the health care payer’s perspective, 
one day spent at home costs 44€ . Survival, QOL and dependence analyses are being 
processed. cOnclusiOns: Continuous- flows LVAD represent a costly strategy in 
the HF treatment but allow the patient to be discharged at home instead of awaiting 
heart transplantation at hospital.
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Objectives: To identify the total in-hospital cost associated with the index hos-
pitalization for the implantation of a left ventricular assistance device (LVAD) in 
a Quebec, Canada setting. MethOds: A retrospective patient chart review was 
conducted in all 3 hospital centers with an active LVAD program to identify all 
patients who underwent LVAD implantation between January 1st 2010 and December 
31st2013. The costing evaluation had 4 distinct components: 1) LVAD acquisition cost; 
2) implantation procedure cost; 3) hospital stay cost; and 4) inpatient drug costs. 
The average cost per patient was calculated. All costs were actualized to 2013 $CDN 
values. Results: A total 65 LVAD-implanted patients were identified between 2010 
and 2013. The majority of these patients were male (n= 49 [75.4%]) and the average 
was 52.2 years old (SD 14.2). Patient-specific costing was completed for 17 of these 
patients. Average index hospitalization stay was 64 days (range 11-140). Average 
per patient cost was $157,073 (range $115,911-222,933). cOnclusiOns: This is the 
first province-wide evaluation of the cost of the index hospitalisation for LVAD 
implantation. These results should inform the decision-making process related to 
future resource allocation for the province’s LVAD program.
